Back to Search
Start Over
BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.
- Source :
-
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Feb; Vol. 67 (2), pp. 299-310. Date of Electronic Publication: 2017 Nov 01. - Publication Year :
- 2018
-
Abstract
- Approximately, 50% of human melanomas are driven by BRAF mutations, which produce tumors that are highly immunosuppressive and often resistant to vaccine therapy. We introduced lipid-coated calcium phosphate nanoparticles (LCP NPs) as a carrier to efficiently deliver a tumor-specific antigen, the BRAF <superscript>V600E</superscript> peptide, to drive dendritic cell (DC) maturation and antigen presentation in C57BL6 mice. The BRAF peptide vaccine elicited a robust, antigen-specific cytotoxic T cell response and potent tumor growth inhibition in a murine BRAF-mutant melanoma model. Advanced BRAF-specific immune response was illustrated by IFN-γ production assay and cytotoxic T lymphocyte (CTL) assay. Remodeling of immunosuppressive modules within the tumor microenvironment further facilitated CTL infiltration. Thus, using LCP NPs to deliver the BRAF peptide vaccine is a promising strategy for the BRAF-mutant melanoma therapy.
- Subjects :
- Animals
Cancer Vaccines immunology
Cell Line, Tumor
Female
Melanoma, Experimental genetics
Mice
Mice, Inbred C57BL
Proto-Oncogene Proteins B-raf genetics
Tumor Microenvironment immunology
Cancer Vaccines pharmacology
Melanoma, Experimental immunology
Melanoma, Experimental therapy
Proto-Oncogene Proteins B-raf immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0851
- Volume :
- 67
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Cancer immunology, immunotherapy : CII
- Publication Type :
- Academic Journal
- Accession number :
- 29094184
- Full Text :
- https://doi.org/10.1007/s00262-017-2079-7